Micromet AG reports new findings on the mode of action of its proprietary class of antibody derivatives called BiTE™. Previous studies have shown that minute doses of BiTE™ molecules can activate cytotoxic T cells against cancer cells resulting in efficient and precise cancer cell destruction without the need for co-stimulation of T cells.
